Crucell

In 2002, CAT granted Crucell a worldwide licence in respect of CAT's Phage Display technology patents. Under the terms of the agreement, CAT received an initial licence fee from Crucell and in return, Crucell and its partners were licensed to develop and commercialise human antibody products against targets using CAT's patented Phage Display technology.

CAT will receive milestone and royalty payments for any antibody products that Crucell or its partners successfully develop that are derived from Crucell's technology.

As a result of this licence agreement, all litigation, which had been ongoing between CAT and Crucell, was withdrawn.